Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03654764 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| PF-03654764 + Allegra | EXPERIMENTAL | - |
| PF-03654764 | EXPERIMENTAL | - |
| Allegra-D | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Cohort 1 | EXPERIMENTAL | Subjects will be assigned to receive either PF-03654764 or placebo. |
| Cohort 2 | EXPERIMENTAL | Subjects will be assigned to receive either PF-03654764 or placebo. |
| Cohort 3 | EXPERIMENTAL | Subjects will be assigned to receive either PF-03654764 or placebo. |
| Name | Type | Description |
|---|---|---|
| PF-03654764 | DRUG | PF-03654764 single dose 5 mg |
| Allegra | DRUG | Fexofenadine single dose 60 mg |
| Allegra-D | DRUG | Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose |
| Placebo | DRUG | Placebo single dose |
Inclusion Criteria: * Male or female subjects 18-60 years allergic to ragweed pollen. * Subjects with appropriate symptom scores following exposure to ragweed in the environmental exposure unit. Exclusion Criteria: * Subjects with significant diseases other than allergic rhinitis that may interfe...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | N/A | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | - | Undisclosed |
PF-03654764 is an investigational small molecule being developed by Pfizer for respiratory conditions, specifically studied in healthy volunteers and in patients with allergic rhinitis. It has been evaluated in clinical trials for safety, toleration, and its effect on symptoms of allergic rhinitis.
PF-03654764 is developed by Pfizer, Inc., which trades under the ticker symbol PFE. The company has sponsored clinical trials of the drug in healthy volunteers and in patients with allergic rhinitis.
PF-03654764 has completed a Phase 2 clinical trial for allergic rhinitis and a Phase 1 trial in healthy volunteers. It is an investigational drug, not approved by regulatory authorities, and no active trials are currently listed.
PF-03654764 has been studied in two completed trials: NCT00989391, a Phase 1 study in healthy people in Singapore to investigate safety, toleration, and blood concentrations, and NCT01033396, a Phase 2 study in Canada evaluating its effect on allergic rhinitis symptoms.
No, PF-03654764 is not the same as Allegra. In a clinical trial, PF-03654764 was studied alone and in combination with Allegra (fexofenadine) to assess its effect on allergic rhinitis symptoms, indicating they are distinct drugs.